๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Systemic Sclerosis
Clinical trial register · China

Systemic Sclerosis Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 5 Beijing 4 Guangzhou 2 Hangzhou 2 Nanjing 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai5 Beijing4 Guangzhou2 Hangzhou2 Nanjing2
All 18 locations
Target enrolment
to

Systemic Sclerosis trials in China

17 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
NCT07596680SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
Nanjing Bioheng Biotech Co., Ltd.
Phase EARLY_PHASE1
30
Shanghai
2026-09-01
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
NCT07558850Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis
The First Affiliated Hospital with Nanjing Medical University
Not applicable
72
Nanjing
2026-05-10
Recruiting
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
NCT06947473Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital
Phase 1/2
45
Beijing
2026-03-18
Recruiting
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT07246096Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis, Primary Sjรถgren Syndrome
Changhai Hospital
Phase EARLY_PHASE1
60
Shanghai
2026-02-20
Recruiting
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
NCT07236801Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Xuzhou
2025-11-13
Not yet open
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
Changzhou No.2 People's Hospital
Phase 1
18
Changzhou
2025-05
Recruiting
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947460Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
Beijing GoBroad Hospital
Phase 1/2
45
Beijing
2025-04-18
Active, closed
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07155369Systemic Lupus Erythematosus, Systemic Sclerosis
The Affiliated Hospital of Xuzhou Medical University
Not applicable
18
Xuzhou
2025-03-18
Recruiting
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
NCT06775912SLE, Systemic Sclerosis, IIM, NMOSD
Nanjing Bioheng Biotech Co., Ltd.
Phase EARLY_PHASE1
18
Lianyungang
2025-01-03
Recruiting
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT06548607SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
DrugCD19
Nanjing Bioheng Biotech Co., Ltd.
Phase EARLY_PHASE1
20
Bengbu
2024-09-14
Recruiting
Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
NCT06414135Systemic Sclerosis
Liangjing Lu
Phase 1
6
Shanghai
2024-06-12
Not yet open
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
NCT06420154Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
First Affiliated Hospital of Wenzhou Medical University
Phase EARLY_PHASE1
9
Wenzhou
2024-05-27
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Recruiting
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
NCT06058091Systemic Sclerosis
Jiangsu Renocell Biotech Company
Phase 1/2
81
Nanjing
2023-09-22
By invitation
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
Bioray Laboratories
Not applicable
15
Shanghai
2023-05-17
Active, closed
A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
NCT05300932Systemic Sclerosis
Tongji Hospital
Phase 4
60
Wuhan
2022-03-08
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/systemic-sclerosis

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies listing the condition Systemic Sclerosis.

How many Systemic Sclerosis trials are recruiting in China?

10 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Systemic Sclerosis), 17 studies
PhaseStudiesRecruitingShare
Phase EARLY_PHASE15329.4%
Not applicable3117.6%
Phase 13217.6%
Phase 1/23317.6%
Phase 32111.8%
Phase 4105.9%

Most active sponsors

Lead sponsors with the most studies (Systemic Sclerosis)
Lead sponsorStudiesRecruiting
Nanjing Bioheng Biotech Co., Ltd.32
Beijing GoBroad Hospital22
AstraZeneca10
Bioray Laboratories10
Boehringer Ingelheim11
Changhai Hospital11
Changzhou No.2 People's Hospital10
China Immunotech (Beijing) Biotechnology Co., Ltd.11
First Affiliated Hospital of Wenzhou Medical University10
Jiangsu Renocell Biotech Company11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.